Sun Piaoyang (#262)
- $ 12 B
- Pharmaceuticals
- China
- M
- 67 Years
'A form of double taxation': Are management fees on new houses quietly getting out of control?
Trump Official Blames Biden Admin for Economic ‘Mess’ — As Resurfaced Clip Shows Him Saying Trump Would Own the Economy By 2026
Is Precigen, Inc. (PGEN) A Good Stock To Buy Now?
Is Transocean Ltd. (RIG) A Good Stock To Buy Now?
Tesla is selling Chinese-made cars in Canada to escape the tariffs that both China and America imposed on it
Insecurity didn’t start with Tinubu, group defends president’s security record
Vibrating pillow sleeve warns deaf sleepers of burglars and fires
How Kepler built verifiable AI for financial services with Claude
Is ASML Holding N.V. (ASML) A Good Stock To Buy Now?
5-Letter Words Ending in ‘Y’ to Help You Improve Your Wordle Skills
About Me
Sun Piaoyang is the chairman of Jiangsu Hengrui Pharmaceuticals. He has turned a formerly state-led business into one of China's largest producers of anti-infection and tumor-treating medicines. He became the head of the state-led company in 1990 when he was 32 years old. After taking Hengrui public in Shanghai in 2000, Sun led the firm to complete a Hong Kong listing in 2025, raising $1.3 billion. Sun's wife Zhong Huijuan, also a billionaire, is the chairman and CEO of Hansoh Pharmaceutical Group, a drug maker that listed on the Hong Kong Stock Exchange in 2019. Their daughter, Sun Yuan, is Hansoh's executive director.
Achievements
Career Highlights
A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Sun Piaoyang’s rise and global influence.
Wealth Growth
Net Worth Growth Over Time
Tracking Sun Piaoyang’s net worth journey over the years, highlighting key growth phases and financial milestones.
Current Net Worth: $11.9B
(May 4, 2026)
© Iconic Billionaires